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Psychedelic drugs reliably trigger experiences that closely resemble synaesthesia (Luke and Terhune 
2013), a condition in which inducer stimuli will reliably and automatically elicit atypical concurrent 
experiences (Ward 2013). These transient episodes are considered controversial because they do not 
meet behavioural diagnostic criteria for developmental synaesthesia (Terhune et al. 2016). However, 
if these behavioural markers are attributable to the consolidation of synaesthetic associations over 
time (Terhune et al. 2016), they should be observed in cases of acquired synaesthesia. Here we report 
a case of drug-induced acquired synaesthesia (LW) that meets standard diagnostic criteria for 
developmental synaesthesia. 
LW is a 29-year-old male who reports continuously experiencing multiple forms of synaesthesia 
for over 7 years since ingesting approximately 70-150mg of 2,5-dimethoxy-4-bromophenethylamine 
(2C-B) (Papaseit et al. 2018), which greatly exceeds the normal dosage (12-24mg) (Shulgin and 
Shulgin 1990) (see Supplementary Materials). LW was contrasted against 10 non-synaesthete 
healthy controls, all of whom provided informed written consent. He reports that his synaesthetic 
associations became more stable over time and his response patterns met inducer-concurrent 
consistency thresholds for week-color and instrument-color, but not chord-color, synaesthesia on a 
standardized battery (Eagleman et al. 2007). He experiences colours as visuospatially co-localized 
with inducing faces (projector synaesthesia (Dixon et al. 2004; Terhune et al. 2015)), which was 
corroborated (Skelton et al. 2009). He reports that none of his immediate family members have 
developmental synaesthesia; two individuals who have known him since before the onset of his 
synaesthesia independently corroborated his reports. The transient induction of synaesthesia-like 
experiences through 2C-B use has been widely reported in online discussion forums of recreational 
drug users as well as in a previous survey of drug users (Luke et al. 2012) but we are unaware of any 
reports of acquired synaesthesia through the use of 2C-B or any other drugs. 
To assess the automaticity of LW’s face-colour synaesthesia, one of the hallmark behavioural 
features of developmental synaesthesia (Ward 2013), he was contrasted against controls on a priming 
task in which face primes were presented prior to judgments of color patches that were either 
congruent or incongruent with the preceding prime according to LW’s face-color associations. LW 
displayed a larger congruency effect (incongruent – congruent) in error rates, 80% [95% CIs: 71, 88], 
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than controls, 2% [0.2, 2.6], t(9)=37.13, p<.001 (Figure 1), reflecting a difference of nearly 39 SDs, 
zcc=38.95 [38.40, 39.56], with a very low probability of occurrence in the general population, pgp=1.8-
9% [1.6-9, 2.1-9]. LW’s congruency effect in response times for correct responses was also larger, 
236ms [24, 507], than that of controls, 20ms [-1, 48], t(9)=5.07, p<.001, corresponding to a difference 
of over 5 SDs, zcc=5.32 [4.63, 5.83], and a very low probability of occurrence, pgp=3-2% [2-2, 8-2]. 
Bootstrap resampling revealed that LW’s response distributions in congruent and incongruent 
conditions were completely independent for error rates and only minimally overlapping for response 
times whereas both sets of distributions overlapped considerably in controls.  
LW’s multiple forms of synesthesia exhibited inducer-concurrent consistency and his face-color 
synesthesia exhibited automaticity, thereby meeting the two most widely used behavioural diagnostic 
criteria for synesthesia (Eagleman et al. 2007; Rothen et al. 2013; Ward 2013). Insofar as these 
criteria are not met by transient episodes of drug-induced synaesthesia, these results are consistent 
with the proposal that automaticity and consistency are byproducts of the over-learning of 
associations rather than behavioural signatures of synaesthesia per se (Terhune et al. 2016).  
Insofar as 2C-B is a partial serotonin agonist (Páleníček et al. 2013; Papaseit et al. 2018), these 
results add to a growing body of evidence implicating serotonin in the development of synaesthesia 
(Brogaard and Gatzia 2016; Luke and Terhune 2013). Although LW did not experience synaesthesia 
prior to consuming 2C-B, we cannot rule out the possibility that 2C-B use interacted with a latent 
predisposition for cortical disinhibition or hyperexcitability (Rothen and Meier 2014; Terhune et al. 
2015). The factors that sustained his synaesthesia are unknown but its continuity is plausibly 
attributable to the excessive dose of 2C-B (Shulgin and Shulgin 1990). Excessive serotonin from 
LW’s 2C-B use (Papaseit et al. 2018) may have triggered elevated glutamate release, and concomitant 
hyperexcitability in visual cortex (Brogaard and Gatzia 2016), a neurophysiological characteristic of 
synaesthesia (Terhune et al. 2015; Terhune et al. 2011). Cortical hyperexcitability may have triggered 
sustained visual colour percepts that were perceived as visuospatially co-localized with environmental 
inducers similar to the induction of hallucinogen persisting perception disorder (HPPD), which may 
also have a serotonergic basis (Litjens et al. 2014; Martinotti et al. 2018).  
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Figure 1. Face-color automaticity in an acquired synaesthete (LW) and controls. Markers reflect 
1,000 bootstrap resamples for LW and control means in congruent and incongruent face-color priming 
conditions. Marginal histograms reflect kernel density plots of the bootstrap distributions. 
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Methods 
Participants 
LW is a 29-year-old left-handed male and native English speaker with 3 years of higher education. He 
reports continuously experiencing multiple forms of synaesthesia for over 7 years since ingesting 
approximately 70-150mg of 2C-B (approximately 3-12 times the normal dosage [12-24mg]) (Shulgin 
and Shulgin 1990) at the age of 22. Ten healthy male participants, who were recruited for a study on 
perception, without reference to synaesthesia, color processing, or drug use, served as controls (see 
Table S1). Controls ranged in age between 20 and 54, M=28.9 [95% CIs: 25.3, 38.0], with years of 
higher education ranging from 0 to 6 (M=3.7; SD=1.6). Seven of the controls were native English 
speakers, four were left-handed, five were right-handed, and one was ambidextrous. None of the 
controls reported having developmental synaesthesia. LW and the controls did not differ in age, 
t(9)=0.01, p=.50, zcc=0.01 [-0.96, 0.40], pgp= 50% [36, 81], or years of education, t(9)=0.41, p=.65, 
zcc=0.43 [-0.92, 0.31], pgp=65% [39, 80]. All participants were compensated for taking part in the 
study and provided informed consent in accordance with local ethical approval. 
 
Materials 
Drug use history. To screen for drug use history, participants completed the Psychoactive Drug 
History Questionnaire (PDHQ) (Sobell et al. 1995). This scale indexes drug use in the following 
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categories: alcohol, cannabis, stimulants, amphetamines and other stimulants, benzodiazepines and 
tranquilizers, sedatives, hypnotics and barbiturates, heroin, street of illicit methadone, other opioids, 
hallucinogens (LSD, PCP, STP, MDA, DAT, mescaline, peyote, mushrooms, ecstasy (MDMA), 
nitrous oxide (NO)), inhalants, and others. The following drugs were added to the existing 
(hallucinogens) category: 2C-B, DMT, ayahuasca, salvia, DXM, 2-CT, ketamine, datura, Amanita 
muscaria, GHB, ether, and kava kava, as these have all been previously associated with reports of 
drug-induced synaesthesia (Luke and Terhune 2013; Luke et al. 2012). 
 
Table S1. Demographic information and drug use history in LW (acquired synaesthete) 
and controls (Ctrl).  
 LW Ctrl Ctrl Ctrl Ctrl Ctrl Ctrl Ctrl Ctrl Ctrl Ctrl 
Age (years) 29 25 31 26 22 30 54 29 25 20 27 
YoE (years) 3 3 5 4 4 3 4 6 3 0 5 
Handedness L R R R L L R R L L/R L 
Face Memory 
(UFMT) 
86 95 77 82 89 85 89 63 82 86 96 
Face-colour 
priming 
           
RT (ms)            
Congruent 576 552 685 581 514 803 754 800 871 667 498 
Incongruent 812 601 663 683 571 802 747 821 900 636 499 
Error rate            
Congruent .139 .013 .055 .575 .014 .055 .041 .041 .055 .055 .082 
Incongruent .940 .023 .051 .618 .028 .032 .051 .074 .060 .092 .111 
Alcohol + + + + + + + + + + + 
Cannabis + + + - + + + + + +* + 
Stimulants & 
amphetamines 
+ + + - - + - - + - - 
Benzodiazepines + - + - + - - - + - - 
Opioids - - + - - - - + + - - 
Hallucinogens Peyote, 
psilocybin, 
MDMA, 
NO,  
2C-B*, 
ketamine, 
Changa, 
cannabis 
MDMA LSD*, MDA, 
mescaline*, 
psilocybin*, 
MDMA, NO, 
2C-B, DMT, 
psilohuasca 
- - LSD*, 
psilocybin*
, MDMA, 
NO, 2C-B, 
salvia, 
ketamine, 
cannabis* 
- - LSD*, 
psilocybin
, 
MDMA*, 
NO, 
Datura 
- - 
Hallucinogen use 
in the previous 6 
months 
Peyote (1) 
Psilocybin(1) 
 
 LSD (4) 
MDA (2) 
Psilocybin (9) 
MDMA (4) 
- - Psilocybin 
(1) 
MDMA (1) 
- - LSD (1) 
MDMA 
(6) 
- - 
Note. YoE= completed years of university education; L/R= ambidextrous; + = previous use; - = no previous use; 2C-B = 2,5-dimethoxy-4-
bromophenethylamine; MDMA= 3,4-Methylenedioxymethamphetamine; LSD=Lysergic acid diethylamide; NO = Nitrous Oxide; DMT = 
N-Dimethyltryptamine; MDA= 3,4-Methylenedioxyamphetamine. * Participant reported synaesthesia under the influence of this drug. 
Numbers denote frequency of use in the previous 6 months. 
 
Synaesthesia screening. All participants completed a questionnaire that provided a definition of 
synaesthesia and specific examples (Terhune et al. 2016). They were presented with descriptions of 
canonical forms of synaesthesia (grapheme-color, sound-color, and spatial sequence) and asked if 
they had these or any other forms of synaesthesia. In addition, they were questioned regarding the 
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experience of synaesthesia under the influence of drugs, which drugs, frequency (“rarely”, “some of 
the time”, “most of the time”, “every time”), and the type(s) of drug-induced synaesthesia. All 
participants completed the synaesthesia battery (Eagleman et al. 2007), a widely-used online 
instrument for assessing inducer-concurrent consistency in different forms of synaesthesia. LW also 
completed the visually-illustrated associator-projector scale (Skelton et al. 2009), which indexes the 
extent to which a synaesthete experiences their phosphenes as images (associator) or visuospatially 
co-localized with the inducer (projector) (Dixon et al. 2004). 
 
Face memory. To assess the extent to which LW may exhibit atypical face processing or face 
memory, participants completed the Unfamiliar Face Memory Test (UFMT; Jansari, in preparation). 
The UFMT is modelled on the long form of the Cambridge Face Memory Test (CFMT; (Russell et al. 
2009)). The task involves learning and recognizing black and white images of male faces generated 
with FaceGen (https://facegen.com). The faces are presented under different learning conditions 
followed by a series of 3-alternative forced choice recognition tests. The task is comprised of five 
different sections with the learning and memory conditions becoming increasingly more difficult. 
Mean accuracy is 83 (SD=11) and the UFMT is able to capture a range of abilities from so-called 
super-recognition to prosopagnosia. UFMT performance correlated highly with CFMT performance 
in a normative sample, r(59)=.83, p<.001 (Jansari, in preparation), thereby demonstrating construct 
validity. 
 
Face-color priming. This task examined whether affective faces associated with specific colors by 
LW would elicit automatic color experiences that would facilitate or interfere with subsequent color 
judgments, as observed in developmental synaesthesia (Gebuis et al. 2009; Terhune et al. 2011). Each 
trial consisted of a blank screen (300ms), a face prime (5.5 x 3.8cm; 1000ms), a blank inter-stimulus 
interval (500ms), and a color patch (5.5 x 3.8cm; 500ms). Participants were instructed to focus on the 
center of the monitor at all times and identify the color of the patch as quickly and as accurately as 
possible by depressing one of four response keys using the index and middle fingers of their left and 
right hands using a keyboard. Face stimuli consisted of four affective faces (anger, disgust, happiness, 
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and surprise) drawn from a validated database (Langner et al. 2010). The faces consisted of 2 white 
females, 1 black male, and 1 white male and the color patches included the colors blue, orange, green, 
and purple. Face-colour pairings (according to LW’s associations) were congruent on 25% of trials. 
 
Procedure 
To ensure consistency, LW and all controls completed the tasks in the same order. In all cases, task 
instructions were presented on the computer monitor and verbally administered by the experimenter. 
After completing the different psychometric measures, participants completed the face-color priming 
task. Participants were positioned approximately 70cm from the screen. Stimulus presentation was 
implemented using PsychoPy2 v1.85.3 (Peirce et al. 2019), on a 21inch desktop computer. In the 
face-colour priming task, participants completed one practice block of 16 trials, followed by three 
experimental blocks of 96 randomized trials, amounting to 288 trials. Participants completed 114 
trials in the UFMT.  
 
Data analysis 
All comparisons of LW and controls were conducted with modified independent t-tests (Crawford and 
Howell 1998) and effect size estimates (zcc) (Crawford et al. 2010) for single-case studies. The 
percentage of the general population (pgp) that displays a more extreme value was estimated from p-
values (Crawford and Garthwaite 2002). Bootstrap resampling (10,000 resamples, bias-corrected and 
accelerated method) (Efron 1987) was used to compute 95% confidence intervals (CIs) for different 
point estimates. Response patterns in the face-color priming task were investigated by analyzing error 
rates and mean response times on correct trials (RTs). Raw data are presented in Table S1. Figure 1 
was created by resampling data (1,000 samples) and iteratively computing the dependent measure in 
each condition. 
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Results 
Case  
LW reports not experiencing synaesthesia during childhood and adolescence including under the 
influence of recreational drugs. In July 2010 at the age of 22, LW first used 2C-B (approximately 10-
15mg) but did not experience synaesthesia. He subsequently ingested a high dose (70-150mg) of 2C-
B in September 2010, which greatly exceeds the normal oral dosage (12-24mg) (Shulgin and Shulgin 
1990), and experienced multiple vivid forms of synaesthesia including day-color, sound-color, 
emotion-color, smell-color, and face-color synaesthesia. He reports that he continued to experience 
these different forms of synaesthesia afterward and continues to report these experiences 7 years after 
this episode (this study was conducted in September 2017). LW reports that his strongest form of this 
condition is face-color synaesthesia, in which faces will involuntarily elicit experiences of color and 
he reports that these effects are enhanced by emotional facial expressions. He experiences colours as 
visuospatially co-localized with inducing faces (projector synaesthesia; (Dixon et al. 2004; Skelton et 
al. 2009; Terhune et al. 2015a; Ward 2013)). LW’s reports closely resemble reported cases of 
developmental face-color synaesthesia (Farina et al. 2017; Terhune et al. 2010; Ward 2013) and his 
associations between color and emotion are consistent with emotion-color links in the general 
population (Dael et al. 2016). He reports that his synaesthesia is attenuated after consumption of 
coffee, alcohol, cigarettes, and cannabis, and enhanced after consumption of ketamine, psilocybin, 
and 2C-B, as previously reported in developmental synaesthesia (Luke and Terhune 2013). LW 
reports that none of his immediate family members have developmental synaesthesia. Two individuals 
who knew LW prior to, and after, the onset of his synaesthesia were interviewed and confirmed that 
he did not report such experiences prior to his 2C-B use, that he first reported these experiences 
shortly after consuming 2C-B in September 2010, and that he has continuously reported synaesthetic 
experiences since that date. 
 
Synaesthesia characteristics 
LW was assessed for inducer-concurrent consistency for three forms of synaesthesia (week-color, 
instrument-color, and chord-color) using the synaesthesia battery (Eagleman et al. 2007). For these 
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three forms, he received scores of 1, 0.49, and 2.01, respectively. Scores of 1 and below have been 
shown to reflect synaesthesia (Eagleman et al. 2007), although this threshold may be too conservative 
(Rothen et al. 2013). These results thereby suggest that LW’s week-color and instrument-color 
synaesthesia meet criteria for consistency as applied in developmental synaesthesia. The use of face-
colour associations in the face-colour priming task further necessitated the consistency of these 
associations as inducer-concurrent automaticity cannot be assessed in the absence of inducer-
concurrent consistency, as previously noted in the study of transient drug-induced synaesthesia-like 
experiences (Terhune et al. 2016). In particular, although not formally tested, LW was able to identify 
four face-colour pairs that were stable over a one-week period, and which were used as stimuli in the 
face-colour priming task (see below). LW completed the associator-projector questionnaire (Skelton 
et al. 2009) in reference to his face-color synaesthesia and received a score of 7, which meets criteria 
for projector synaesthesia (>4.3) and is thereby consistent with his reports that synaesthetic colour are 
perceived as visuospatially co-localized with inducers.  
 
Face memory 
A wealth of evidence suggests that synaesthetes display superior memory on a range of tasks (Rothen 
et al. 2012). In order to determine whether LW displayed atypical face processing or memory, we 
compared his performance on the UFMT against that of controls. LW responded correctly on 86 (out 
of 114) trials, which was comparable to the controls’ performance, M=84.4 [77.4, 88.9], t(9)=0.16, 
p=.44, zcc=0.17 [-0.30, 0.92], pgp=44% [20, 61] (Table S1). All participants scored within 2 SDs of the 
mean performance in a previous normative sample (M=83, SD=11; Jansari, in preparation). These 
data suggest that LW has normal face memory. 
!
 
Drug use 
LW and controls exhibited similar patterns of past drug use overall although LW tended to report a 
greater history of drug use than most controls with only 3 controls having a comparable history, 2 of 
whom had histories that exceeded LW’s history (Table S1). 4 controls (40%) reported previous 
experience of drug-induced synaesthesia, in all cases with psychedelic drugs, cannabis, or MDMA, as 
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previously reported (Luke and Terhune 2013; Luke et al. 2012). LW and 3 controls reported having 
used hallucinogens in the 6 months preceding the study. Cumulatively, these reports corroborate the 
occurrence of drug-induced synaesthesia in the general population (Luke and Terhune 2013; Luke et 
al. 2012) and suggest that LW’s drug use history is in the upper range of males in his age range but is 
not atypical. 
 
Face-colour automaticity 
LW’s consistent face-colour associations were used to present congruent and incongruent face primes 
prior to colour judgments. In addition to the effects reported in the main text (Figure 1 and Table 
S1), LW exhibited numerically faster response times on congruent trials, 576ms [498, 667], than 
controls, 672ms [597, 751], suggesting a moderate facilitation effect of congruent primes, zcc=0.73 
[0.13, 1.31], but this effect did not achieve statistical significance, t(9)=0.69, p=.75, pgp=75% [55, 88].  
 
Discussion 
The present case speaks to a long-standing debate regarding whether drug-induced synaesthesia-like 
experiences qualify as genuine synaesthesia (Brogaard and Gatzia 2016; Luke and Terhune 2013; 
Sinke et al. 2012; Terhune et al. 2016). LW’s multiple forms of synesthesia exhibited inducer-
concurrent consistency and his face-color synesthesia exhibited automaticity, thereby meeting the two 
most widely used behavioural diagnostic criteria for this condition (Eagleman et al. 2007; Rothen et 
al. 2013; Ward 2013). In addition, the specific variant of his most prominent form of synaesthesia 
closely approximates previous cases of developmental face-colour synaesthesia (Terhune et al. 2010). 
These results cumulatively suggest that LW’s experiences qualify as genuine synaesthesia. His 
synaesthesia appears to have arisen following a single dose of the recreational psychedelic drug 2C-B, 
a partial serotonin agonist (Páleníček et al. 2013; Papaseit et al. 2018), and thereby points to the 
acquisition of synaesthesia through the use of psychedelic drugs and thereby implicates serotonin in 
the development of synaesthesia (Brogaard 2013; Brogaard and Gatzia 2016; Luke and Terhune 2013; 
Terhune et al. 2016). 
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The present results expand upon previous research implicating psychedelic drugs in the induction 
of spontaneous synaesthesia-like experiences (Brogaard and Gatzia 2016; Luke and Terhune 2013). 
Despite reliable evidence for the induction of such episodes, a recent laboratory study found that 
LSD-induced synaesthesia did not exhibit inducer-concurrent consistency (Terhune et al. 2016). By 
contrast, LW’s synaesthesia met standard diagnostic behavioural criteria for both consistency and 
automaticity (Rothen et al. 2013; Ward 2013). This result is consistent with the hypothesis that these 
two markers are actually the by-product of over-learning of synaesthetic associations rather than 
signatures of synaesthesia per se (Terhune et al. 2017; Terhune et al. 2016) (see also (Rothen et al. 
2018; Simner et al. 2009). A corollary of this consolidation hypothesis is that these criteria are not 
useful for evaluating transient episodes of synaesthesia, only those that have undergone consolidation. 
To our knowledge, no previous cases of acquired synaesthesia have been evaluated against these 
diagnostic criteria (Afra et al. 2009; Alstadhaug and Benjaminsen 2010; Fornazzari et al. 2012; Goller 
et al. 2013; Roberts and Shenker 2016; Schweizer et al. 2013). We expect that cases of acquired 
synaesthesia will not meet diagnostic behavioural criteria at early stages, as observed in our previous 
study of drug-induced synaesthesia (Terhune et al. 2016), but that continued experience of 
synaesthesia will drive consolidation of inducer-concurrent associations, as found in developmental 
synaesthesia (Simner et al. 2009), eventually leading to automaticity and consistency, as shown in 
training studies with non-synaesthetes (Rothen et al. 2018). 
A striking feature of the present case that contrasts with those previously reported in the literature 
(Luke and Terhune 2013) is that LW’s synaesthesia persisted for over seven years. The transition 
from a transient episode to a continuous acquired condition is plausibly attributable to the excessive 
dose of 2C-B, which greatly exceeded the normal recreational dose of this drug (Shulgin and Shulgin 
1990). Excessive serotonin from LW’s 2C-B overdose (Papaseit et al. 2018) may have triggered 
elevated glutamate release and concomitant hyperexcitability in visual cortex (Brogaard 2013; 
Brogaard and Gatzia 2016), a neurophysiological characteristic of developmental synaesthesia 
(Terhune et al. 2015a; Terhune et al. 2011). Cortical hyperexcitability may have resulted in sustained 
visual colour percepts that were perceived as visuospatially co-localized with environmental inducers 
in a similar manner to the induction of hallucinogen persisting perception disorder (HPPD) (Litjens et 
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al. 2014; Martinotti et al. 2018). HPPD is characterized by the sustained or recurrent experience of 
(primarily visual) perceptual distortions in the absence of recent drug use and may also have a 
serotonergic basis (Litjens et al. 2014; Martinotti et al. 2018). LW’s face-colour synaesthesia is 
phenomenologically similar to reports of coloured halos around objects in HPPD and synaesthesia is 
among the set of visual disturbances reported in this disorder. The induction of synaesthesia might 
have been facilitated by increased functional connectivity in multisensory pathways as preliminary 
non-human animal research suggests that at high doses (50mg/kg), 2C-B enhances functional 
connectivity in upper beta (25-30Hz) and lower gamma (30-40Hz) bands (Páleníček et al. 2013), both 
of which have been implicated in developmental synaesthesia (Brauchli et al. 2018; Terhune et al. 
2015b). Impaired lateral geniculate nucleus functioning in the thalamus has been suggested to play a 
role in HPPD (Martinotti et al. 2018), which also potentially aligns with cases of acquired 
synaesthesia after thalamic stroke (Fornazzari et al. 2012; Schweizer et al. 2013). Despite these 
parallels, it remains an open question under what circumstances HPPD may give rise to acquired 
synaesthesia. By contrast, insofar as a single dose of 2C-B is unlikely to produce radical and focal 
changes in brain structure connectivity (Brogaard and Gatzia 2016), these results challenge the view 
that structural hyperconnectivity is a causal antecedent to synaesthesia (Hubbard et al. 2011). Rather, 
they suggest instead that, structural brain differences in synaesthesia are a consequence of the 
consolidation of synaesthetic associations (Cohen Kadosh and Walsh 2008; Terhune et al. 2016).  
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